Wegovy at BMI 30: who qualifies and what the licence actually says

Wegovy (semaglutide injection) is licensed in the UK for adults with a BMI of 30 or above, or 27–29.9 with a weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes.
A BMI of 30 qualifies on its own under the licensed threshold — no additional health condition is required at that cut-off.
For some South Asian, Chinese, Middle Eastern, Black African and African-Caribbean backgrounds, UK guidance applies BMI thresholds that are 2.5 kg/m² lower, meaning eligibility may be reached sooner.
BMI is one criterion among several: age, medical history, current medicines and other factors are all assessed by the prescriber before treatment is approved.

A BMI of exactly 30 sits right on the boundary of Wegovy's licensed eligibility criteria in the UK. Semaglutide (Wegovy) is approved for adults with a BMI of 30 or above, or for those with a BMI of 27 to 29.9 who have at least one weight-related health condition. So yes, a BMI of 30 does meet the threshold — but the number alone is only part of the picture. Wegovy is a prescription-only treatment, and a qualified prescriber reviews your whole health profile, not just a single figure, before deciding whether it's right for you.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What BMI 30 actually means for your Wegovy eligibility in practice

You're at BMI 30, here's where the eligibility conversation usually starts

Picture this: you've checked your BMI, it's come back at 30.0 or just above, and you're wondering whether that's enough to be considered for Wegovy. The short answer is yes, in licensing terms it is. The Wegovy SmPC (the document that governs how the medicine is authorised in the UK) sets the lower boundary at a BMI of 30. You don't need a diagnosed comorbidity at that threshold. The 27–29.9 range is where an additional condition (high blood pressure, type 2 diabetes, obstructive sleep apnoea, and so on) becomes the deciding factor. At 30, the BMI itself carries the eligibility.

That said, reaching the threshold isn't the same as being approved. A prescriber will look at your full health picture: your medical history, any medicines you already take, conditions that might make semaglutide unsuitable, and whether the potential benefit genuinely outweighs any risk for you specifically. The full eligibility criteria for Wegovy cover more ground than a single number.

One practical note: BMI is calculated from the height and weight you declare, and at nume that weight is verified on a live video call, not taken on trust. It protects you and it's one of the things that makes a clinical assessment meaningful rather than cursory.

How the NHS eligibility criteria differ from the private licensed threshold

There's a gap worth knowing about. The licensed threshold (BMI 30+) is what governs private prescription routes. The NHS operates under NICE guidance, which sets a higher bar for publicly funded treatment. NICE's appraisal of semaglutide (TA875) recommends it for use within specialist weight management services, for adults with a BMI of 35 or above and at least one weight-related comorbidity, with the usual 2.5 kg/m² ethnic-background adjustment bringing that to around 32.5 for some groups. At BMI 30, you almost certainly won't qualify for Wegovy on the NHS under current criteria, even if you meet the licensed threshold for private treatment.

NHS waiting lists for specialist services are also long in most areas. For people who meet the clinical criteria for private treatment but don't meet NHS thresholds, or who'd rather not wait, a regulated private pharmacy is the alternative. You can find out more about how Wegovy is priced privately if you're weighing up your options. What matters most is that whichever route you take, the prescriber who reviews your case is real, qualified and accountable, not a form that approves you automatically.

What about BMI just under 30, or slightly above?

If your BMI is 29 or 28, the picture shifts. A reading of BMI 28 puts you in the 27–29.9 bracket, where Wegovy's licence requires at least one weight-related condition alongside it. High blood pressure, raised cholesterol, prediabetes, obstructive sleep apnoea and type 2 diabetes are all examples that could qualify you. Without one of those, the licensed threshold isn't met. There's a fuller look at Wegovy eligibility when BMI is under 30 if that's where you are.

At the other end, a BMI a point or two above 30 doesn't change the clinical picture dramatically, you meet the threshold either way. What changes as BMI rises is often the clinical urgency and the number of comorbidities involved, which can shape the prescriber's assessment of how much benefit treatment is likely to offer. The BMI range at which Wegovy is considered is a broader topic than any single cut-off.

If you're not certain where your BMI actually sits, the NHS BMI calculator is a reliable starting point before you go any further.

Starting a private consultation when you're at the eligibility boundary

Sitting right at a threshold can feel uncertain, you're not comfortably inside it, and you might worry a prescriber will turn you away for a reason you haven't anticipated. That's a fair concern, and it's exactly what a proper clinical assessment is for. At nume, a GPhC-registered Independent Prescriber reads every consultation the same day it arrives. Not a triage algorithm, not a scoring tool, a named clinician who can see the nuance in your answers.

If you order before midday on a working day and your consultation is approved, your treatment is dispatched the same day and arrives with DPD the next working morning, in plain packaging. If you don't qualify, you'll hear that clearly too, with a note on why. You can explore all the weight-loss treatment options we offer, or go straight to check your eligibility with a free consultation, there's no obligation and no fee unless treatment is prescribed.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions